Latest News

Thyroidectomy Beneficial but Risky for Hashimoto Disease


 

TOPLINE:

In patients with Hashimoto disease and persistent symptoms despite adequate medical treatment, total thyroidectomy had a beneficial effect up to 5 years but with a substantially higher risk for complications than initially anticipated.

METHODOLOGY:

  • The 5-year follow-up of 65 participants in a randomized, open-label trial of thyroidectomy plus medical management vs medical management alone aimed at testing the hypothesis that persistent symptoms despite adequate thyroxine replacement may be related to extrathyroidal autoimmune reactions and that complete removal of thyroid tissues may attenuate autoimmune responses and relieve symptoms.
  • Patients in the control group were given the option of having surgery 18 months after enrollment, depending on trial results.
  • The primary outcome was patient-reported health-related quality of life measured by the dimensional general health score in the generic Short Form-36 Health Survey questionnaire.

TAKEAWAY:

  • The positive treatment effect seen after 18 months was maintained throughout the 3-year follow-up.
  • In the intervention group, the improved general health score remained at the same level during the 5-year follow-up.
  • Results were similar for the other Short Form-36 Health Survey domains and for total fatigue and chronic fatigue.
  • Short-term (<12 months) or longer-lasting complications occurred in 23 patients, including 6 with recurrent laryngeal nerve paralysis (4 were long-term) and 12 with hypoparathyroidism (6 long-term, including 3 permanent).
  • Five patients had postoperative hematoma and/or infection requiring intervention.

IN PRACTICE:

“The improvements in patient-reported outcome measures reported at 18 months after surgery were maintained at 5 years after surgery in the intervention group. In contrast, no spontaneous improvement was seen during 3 years in the control group.”

“Long-term complications in 10 of 73 (14%) patients despite use of meticulous dissection to achieve total thyroidectomy is unacceptably high. Medication and compensatory mechanisms for hypoparathyroidism and unilateral recurrent nerve injury, respectively, did alleviate symptoms.”

SOURCE:

This study was published in Annals of Internal Medicine, by Geir Hoff, MD, PhD, of the Department of Research, Telemark Hospital, Skien, and the Institute of Clinical Medicine, University of Oslo, Oslo, Norway, and colleagues.

LIMITATIONS:

None listed.

DISCLOSURES:

None.

Recommended Reading

Triple therapy boosts anaplastic thyroid cancer survival
MDedge Endocrinology
Measures of PTH predict postthyroidectomy hypocalcemia
MDedge Endocrinology
Hold blood thinners during thyroid nodule biopsy?
MDedge Endocrinology
Thyroid cancer increase observed in transgender female veterans
MDedge Endocrinology
Does an elevated TSH value always require therapy?
MDedge Endocrinology
Nonsurgical option for more large thyroid nodule patients?
MDedge Endocrinology
Be advised: Thyroid hormones may increase risk of cognitive disorders in older adults
MDedge Endocrinology
Pervasive ‘forever chemicals’ linked to thyroid cancer?
MDedge Endocrinology
Anti-Rheumatic Drugs Linked to Reduced Thyroid Disease Incidence
MDedge Endocrinology
Study Suggests Inappropriate Use of Thyroid Ultrasounds
MDedge Endocrinology